Saniona, a clinical stage biopharmaceutical company focused on rare diseases, completed the submission of all information requested by the U.S. FDA regarding its chemistry, manufacturing and controls (CMC) program for Tesomet capsules. With this submission completed, Saniona expects to be able to initiate its Phase 2b clinical trials for Tesomet before the end of 2021.   Tesomet as a capsule can offer potential advantages over a tablet to people living with Prader-Willi syndrome or hypothalami...